Literature DB >> 29885481

Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.

Naoki Haratake1, Tetsuzo Tagawa2, Fumihiko Hirai1, Gouji Toyokawa1, Reiko Miyazaki3, Yoshihiko Maehara4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29885481     DOI： 10.1016/j.jtho.2018.05.031

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.

Authors:  Matin Dokht Ashoori; Kensuke Suzuki; Yosuke Tokumaru; Naoko Ikuta; Masaki Tajima; Tasuku Honjo; Akio Ohta
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

2.  Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review.

Authors:  Yidong Zhao; Yuzhen Cao; Xiuyu Wang; Tianyi Qian
Journal:  Onco Targets Ther       Date:  2022-04-08       Impact factor: 4.147

3.  Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.

Authors:  Jing-Yi Wu; Kai Kang; Jing Yi; Bin Yang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 4.  [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.